Pharmaceuticals company Ipca Laboratories announced Q4FY26 & FY26 results Consolidated Financial Highlights: Total Income: Consolidated total income for Q4FY26 was Rs 2,482.22 crore, an increase of 2.88% QoQ from Rs 2,412.69 crore in Q3FY26 and an increase of 9.23% YoY from Rs 2,272.51 crore in Q4FY25. For the full year FY26, consolidated total income was Rs 9,820.78 crore, up 8.73% from Rs 9,032.39 crore in FY25. Revenue from Operations: Consolidated revenue for Q4FY26 stood at Rs 2,388.48 crore, which was largely flat QoQ (-0.17%) compared to Rs 2,392.50 crore in Q3FY26, and grew 6.31% YoY from Rs 2,246.69 crore in Q4FY25. Annual consolidated revenue for FY26 reached Rs 9,646.33 crore against Rs 8,939.59 crore in FY25. Net Profit (Attributable to Owners): Consolidated Net Profit for Q4FY26 was Rs 299.07 crore, down 8.34% QoQ from Rs 326.27 crore in Q3FY26 but up 340.98% YoY from Rs 67.82 crore in Q4FY25. For the full year FY26, consolidated Net Profit grew by 54.69% to Rs 1,141.12 crore from Rs 737.68 crore in FY25. EBITDA: Consolidated EBITDA (before forex gain/loss, other income, and exceptional items) for Q4FY26 was Rs 490.21 crore, up 20% YoY from Rs 409.74 crore in Q4FY25. For FY26, EBITDA grew 18% to Rs 1,998.96 crore from Rs 1,693.13 crore in FY25. Earnings Per Share (EPS): Consolidated basic EPS for Q4FY26 was Rs 11.79. For the full year FY26, it was Rs 44.98 compared to Rs 29.08 in FY25. Standalone Financial Highlights: Total Income: For Q4FY26, standalone total income stood at Rs 1,844.23 crore, representing a decrease of 1.01% QoQ compared to Rs 1,863.00 crore in Q3FY26, and an increase of 11.10% YoY from Rs 1,659.93 crore in Q4FY25. For the full year FY26, total income reached Rs 7,431.39 crore, up 10.11% from Rs 6,749.21 crore in FY25. Revenue from Operations: In Q4FY26, standalone revenue was Rs 1,814.35 crore, down 1.67% QoQ from Rs 1,845.18 crore in Q3FY26 and up 10.74% YoY from Rs 1,638.44 crore in Q4FY25. Annual revenue for FY26 stood at Rs 7,336.75 crore compared to Rs 6,677.92 crore in FY25. Net Profit: The standalone Net Profit for Q4FY26 was Rs 262.29 crore, a decline of 13.56% QoQ from Rs 303.45 crore in Q3FY26, but showing a significant recovery compared to a loss of Rs 65.05 crore in Q4FY25. For the full year FY26, Net Profit grew by 74.03% to Rs 1,132.52 crore from Rs 650.76 crore in FY25. Earnings Per Share (EPS): Basic EPS for Q4FY26 was Rs 10.34. For the full year FY26, basic EPS stood at Rs 44.64 compared to Rs 25.65 in FY25. Business Highlights Segment Performance: The group operates in a single reportable segment, namely "Pharmaceuticals". Geographic Performance (Q4FY26): Indian Formulations: Income grew by 12% YoY to Rs 853.33 crore. Exports Income: Total export formulations and APIs grew by 9% YoY to Rs 845.53 crore. Branded formulations exports grew by 14% to Rs 190.17 crore, while Generics formulations exports surged 39% to Rs 341.02 crore. Yearly Revenue Break-up (FY26): Domestic Formulations: Rs 3,817.24 crore, up 10% YoY. Export Formulations: Rs 2,082.58 crore, up 10% YoY. Export APIs: Rs 1,046.85 crore, up 18% YoY. Dividend: The Board has recommended a dividend of Rs 6/- per share of Re 1/- each (600%) for the financial year ended March 31, 2026. Exceptional Items: For FY26, the company recorded an exceptional charge of Rs 45.82 crore (Consolidated) and Rs 30.42 crore (Standalone) related to the "Impact of new Labour Codes" due to revised pay structures and enhanced employee benefits. Subsidiary Developments: During the year, the company acquired a 100% equity interest in Unichem Laboratories Limited, Ireland, and incorporated a wholly-owned subsidiary in Germany. Result PDF